Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)’s share price dropped 1.4% during mid-day trading on Tuesday . The stock traded as low as $5.42 and last traded at $5.45, with a volume of 751,072 shares trading hands. The stock had previously closed at $5.53.

ARLZ has been the subject of several analyst reports. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Aralez Pharmaceuticals in a research note on Sunday, August 14th.

The firm has a 50-day moving average price of $4.03 and a 200 day moving average price of $4.21. The stock’s market capitalization is $355.56 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $9.70 million. The business’s revenue for the quarter was up 142.3% on a year-over-year basis. On average, analysts expect that Aralez Pharmaceuticals Inc. will post ($0.98) EPS for the current fiscal year.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.